# A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

Study · id `cardio:ct-nct07421284` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07421284](<https://clinicaltrials.gov/study/NCT07421284>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07421284

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 900 participants.

## Technical summary

Registry record NCT07421284. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-31 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 900 participants (planned count; ClinicalTrials.gov record NCT07421284, source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)
- Planned start: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT07421284, source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07421284, source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07421284, source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07421284, source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07421284-2026-02-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
- Condition: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- Intervention (Drug): SYH2053/placebo injection
- Lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (`cardio:org-cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd`)

## Provenance

Content hash: d291488e826211646d18c48b21b688271954e4185d4692d71ea983aacf443bf1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
